A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
BACKGROUND: Abdominoplasty in patients with obesity carries a heightened risk of venous thromboembolism (VTE) due to a proinflammatory and hypercoagulable baseline. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weigh…
AIMS: Targeting the glucose dependent insulinotropic polypeptide receptor (GIPR) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporate…
Obesity is a chronic, highly prevalent disease affecting nearly one-third of the global population and represents a major independent risk factor for heart failure (HF), particularly heart failure with preserved ejection fraction (HFpEF). Excess adip…
Objective Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to improve hepatic inflammation and steatosis in patients with type 2 diabetes. However, whether its…
PURPOSE: This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological…
BACKGROUND: While glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor/GIP agonists (GLPs) have revolutionized the treatment of obesity, national data shows Black patients, Hispanic patients, and patients of lower socio…
INTRODUCTION: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss. METHODS: Systematic review and network meta-analysis of randomized controlled…
Background and AimEmerging evidence suggests that weight loss associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be in part attributable to changes in lean mass, which has potential clinical implications. This study evaluates t…
Tirzepatide, a dual GIP/GLP-1 receptor agonist, shows promise in managing obesity and type 2 diabetes. This bibliometric analysis maps its research landscape, identifying trends, collaborations, and emerging themes to guide future investigations. A s…
The year 2025 represented a turning point in metabolic research, marked by advances that combined unprecedented clinical efficacy with deep mechanistic insight. Landmark obesity trials redefined therapeutic expectations, with head-to-head and combina…
IMPORTANCE: The dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide was noninferior to a GLP-1 agonist, dulaglutide, for effects on the composite outcome of cardiovascular death, myocardial…
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual incretin agonist tirzepatide have demonstrated cardiometabolic benefits in cardiovascular outcome trials, but their effects on limb outcomes in peripheral artery disease (PAD) re…
AIMS: This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. MATERIALS AND METHODS: This was a prespecified subgroup analysis of the SURMOUNT-J trial. Japa…
Tamoxifen, a selective estrogen receptor modulator (SERM), is commonly prescribed in hormone receptor-positive breast cancer. While effective in reducing recurrence and mortality, tamoxifen is associated with weight gain in a significant proportion o…
INTRODUCTION: Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no cure. Diabetes is one of the risk factors for developing PD. Tirzepatide is a novel long-acting glucagon-like peptide-1 (GLP-1) and glucose-depen…
GLP-1-based drugs are approved for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 60% of patients with T2DM, and the gut microbiome plays a critical rol…